Review



breast cancer cell lines t47d  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    ATCC breast cancer cell lines t47d
    Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 6864 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/us12571798-2703-0-13
    Average 99 stars, based on 6864 article reviews
    breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars

    Images

    Related Articles

    Multiple Displacement Amplification:

    Article Title: RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis
    Article Snippet: ZVAD-FMK (an apoptosis inhibitor) and necrosulfonamide (a necroptosis inhibitor) were purchased from Sigma (St. Louis, MO, USA). .. Two breast cancer cell lines T47D and MDA-MB-231 were purchased from ATCC, and cultured in DMEM medium. ..

    Article Title: RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis.
    Article Snippet: ZVAD-FMK (an apoptosis inhibitor) and necrosulfonamide (a necroptosis inhibitor) were purchased from Sigma (St. Louis, MO, USA). .. Two breast cancer cell lines T47D and MDA-MB-231 were purchased from ATCC, and cultured in DMEM medium. ..

    Article Title: LDAcoop: Integrating non-linear population dynamics into the analysis of clonogenic growth in vitro.
    Article Snippet: .. The breast cancer cell lines T47D (RRID: CVCL_0553), SKBR3 (RRID:CVCL_0033), BT20 (RRID:CVCL_0178), MDA-MB231 (RRID:CVCL_ 0062), HCC1806 (RRID:CVCL_1258), and DU4475 (RRID:CVCL_1183), and the lung cancer cell lines A549 (RRID:CVCL_0023) and SKLU1 (RRID: CVCL_0629) were purchased from either ATCC (Manassas, VA, USA), CLS (Heidelberg, Germany), Molecular Oncology (2025) a 2025 The Author(s). ..

    Article Title: New Phenolic Glycosides from Coelogyne fuscescens Lindl. var. brunnea and Their Cytotoxicity against Human Breast Cancer Cells
    Article Snippet: .. The breast cancer cell lines T47D (human hormone-dependent breast cancer) and MDA-MB-231 (a highly aggressive, invasive, and poorly differentiated triple-negative breast cancer) as well as the human normal keratinocyte HaCaT cell line were obtained from the American Type Culture Collection (Manassas, VA, USA). .. Dulbecco’s modified eagle Medium (Gibco, Grand Island, NY, USA) was used for culturing T47D, MDA-MB-231, and HaCaT cell lines.

    Article Title: SB218078 inhibits angiogenesis and epithelial-mesenchymal transition in breast cancer
    Article Snippet: Fetal bovine serum (FBS), RPMI-1640 medium, Penicillin-Streptomycin solution, and 0.25% trypsin were all obtained from Invitrogen (Carlsbad, CA). .. Human umbilical vein endothelial cells (HUVECs), along with breast cancer cell lines T47D and MDA-MB-231, were obtained from ATCC. ..

    Article Title: Cancer biomarkers and methods of use thereof
    Article Snippet: .. Breast cancer cell lines T47D, SKBr3, BT549 and MDA-MB-231 were obtained from the ATCC. ..

    Article Title: Cancer biomarkers and methods of use thereof
    Article Snippet: .. Breast cancer cell lines T47D, SKBr3, BT549 and MDA-MB-231 were obtained from the ATCC. ..

    Cell Culture:

    Article Title: RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis
    Article Snippet: ZVAD-FMK (an apoptosis inhibitor) and necrosulfonamide (a necroptosis inhibitor) were purchased from Sigma (St. Louis, MO, USA). .. Two breast cancer cell lines T47D and MDA-MB-231 were purchased from ATCC, and cultured in DMEM medium. ..

    Article Title: RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis.
    Article Snippet: ZVAD-FMK (an apoptosis inhibitor) and necrosulfonamide (a necroptosis inhibitor) were purchased from Sigma (St. Louis, MO, USA). .. Two breast cancer cell lines T47D and MDA-MB-231 were purchased from ATCC, and cultured in DMEM medium. ..

    other:

    Article Title: Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy
    Article Snippet: Ovarian cancer cell lines OVSAHO, SKOV3, COV362, CaOV3 and breast cancer cell lines T47D and MCF7 were obtained from the American Type Culture Collection (ATCC).



    Similar Products

    breast cancer cell lines t47d  (ATCC)
    99
    ATCC breast cancer cell lines t47d
    Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/us12571798-2703-0-13
    Average 99 stars, based on 1 article reviews
    breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    t47d breast cancer cell lines  (ATCC)
    99
    ATCC t47d breast cancer cell lines
    T47d Breast Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/bio_rxiv__64898__2026__01__06__697866-267-2-10
    Average 99 stars, based on 1 article reviews
    t47d breast cancer cell lines - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    human breast cancer cell lines t47d  (ATCC)
    99
    ATCC human breast cancer cell lines t47d
    Human Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/10__31083_slash_fbl45389-51-0-28
    Average 99 stars, based on 1 article reviews
    human breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    t47d human breast cancer cell line  (Pasteur Institute)
    86
    Pasteur Institute t47d human breast cancer cell line
    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on <t>T47D</t> cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.
    T47d Human Breast Cancer Cell Line, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/7+mcf/pmc12783725-25-1-11
    Average 86 stars, based on 1 article reviews
    t47d human breast cancer cell line - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    tumour breast cancer cell lines t47d  (ATCC)
    99
    ATCC tumour breast cancer cell lines t47d
    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on <t>T47D</t> cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.
    Tumour Breast Cancer Cell Lines T47d, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/pmc12574668-32-19-29
    Average 99 stars, based on 1 article reviews
    tumour breast cancer cell lines t47d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    breast cancer cell line t47d cells  (ATCC)
    99
    ATCC breast cancer cell line t47d cells
    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on <t>T47D</t> cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.
    Breast Cancer Cell Line T47d Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/breast+cancer+cell+lines+t47d/T-47D/us12479928-755-1-7
    Average 99 stars, based on 1 article reviews
    breast cancer cell line t47d cells - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on T47D cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Synergistic cytotoxic effect of 17-AAG-loaded PEG-CS nanoparticles and trastuzumab on T47D cells. Cell viability was assessed by MTT assay after 72 h of treatment. Data are presented as mean ± SD ( n = 3). The combination group (17-AAG-loaded NPs + trastuzumab) showed significantly reduced cell viability (15%) compared to treatment with 17-AAG-loaded NPs alone (50%), trastuzumab alone (35%), or blank NPs + trastuzumab (100%). Statistical significance: **** p < 0.0001 vs. Blank NPs + Trastuzumab group (one-way ANOVA with Tukey’s post-hoc test). The Combination Index (CI) calculated using CompuSyn software was 0.72, indicating strong synergy.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: MTT Assay, Software

    In vitro cytotoxicity of 17-AAG-loaded PEG-CS NPs in T47D and MDA-MB-231 cells. Cell viability after 72 h treatment with free 17-AAG or 17-AAG-loaded NPs. The nanoformulation showed significantly enhanced cytotoxicity, with an IC₅₀ of 2.3 ± 0.3 µM in T47D cells, representing a threefold increase compared to free 17-AAG (IC₅₀ = 6.9 ± 0.5 µM). Similar results were observed in MDA-MB-231 cells (IC₅₀ = 3.0 µM for NPs vs. 8.1 µM for free drug). Blank PEG-CS NPs showed no significant toxicity in NHDF cells (up to 50 µg/mL). Data are mean ± SEM ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test. **** P < 0.0001 vs. control.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: In vitro cytotoxicity of 17-AAG-loaded PEG-CS NPs in T47D and MDA-MB-231 cells. Cell viability after 72 h treatment with free 17-AAG or 17-AAG-loaded NPs. The nanoformulation showed significantly enhanced cytotoxicity, with an IC₅₀ of 2.3 ± 0.3 µM in T47D cells, representing a threefold increase compared to free 17-AAG (IC₅₀ = 6.9 ± 0.5 µM). Similar results were observed in MDA-MB-231 cells (IC₅₀ = 3.0 µM for NPs vs. 8.1 µM for free drug). Blank PEG-CS NPs showed no significant toxicity in NHDF cells (up to 50 µg/mL). Data are mean ± SEM ( n = 3). Statistical significance was determined by one-way ANOVA followed by Tukey’s post-hoc test. **** P < 0.0001 vs. control.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: In Vitro, Control

    Flow cytometric analysis of apoptosis in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. A Untreated control cells. B Cells treated with 17-AAG-loaded PEG-CS NPs. The percentage of apoptotic cells (Q2 + Q3) increased from 16.5% in the control group to 52.2% in the treated group. Data are representative of three independent experiments ( n = 3).

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Flow cytometric analysis of apoptosis in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. A Untreated control cells. B Cells treated with 17-AAG-loaded PEG-CS NPs. The percentage of apoptotic cells (Q2 + Q3) increased from 16.5% in the control group to 52.2% in the treated group. Data are representative of three independent experiments ( n = 3).

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Control

    Cell cycle distribution in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. The treated group showed an increase in the G2/M phase (26.50%) compared to control (19.30%), indicating G2/M arrest. Data are representative of three independent experiments ( n = 3).

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: Cell cycle distribution in T47D cells after 24 h treatment with 17-AAG-loaded PEG-CS NPs. The treated group showed an increase in the G2/M phase (26.50%) compared to control (19.30%), indicating G2/M arrest. Data are representative of three independent experiments ( n = 3).

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Control

    qRT-PCR analysis of HSP90 and β-actin gene expression in T47D cells after 72 h treatment with 17-AAG-loaded PEG-CS NPs. A Melting curves for HSP90 (Tm = 78.2 °C) and β-actin (Tm = 83.9 °C), showing single sharp peaks that confirm the specificity of amplification and absence of primer-dimers. Data are representative of three independent experiments ( n = 3). B Amplification curves for HSP90 (purple line) and β-actin (blue line) genes, showing the cycle threshold (Ct) values used for relative quantification of gene expression.

    Journal: Scientific Reports

    Article Title: Development of a pH-responsive pegylated chitosan nanocarrier for targeted delivery of 17-AAG and synergistic therapy in HER2 + breast cancer

    doi: 10.1038/s41598-025-30507-2

    Figure Lengend Snippet: qRT-PCR analysis of HSP90 and β-actin gene expression in T47D cells after 72 h treatment with 17-AAG-loaded PEG-CS NPs. A Melting curves for HSP90 (Tm = 78.2 °C) and β-actin (Tm = 83.9 °C), showing single sharp peaks that confirm the specificity of amplification and absence of primer-dimers. Data are representative of three independent experiments ( n = 3). B Amplification curves for HSP90 (purple line) and β-actin (blue line) genes, showing the cycle threshold (Ct) values used for relative quantification of gene expression.

    Article Snippet: The T47D human breast cancer cell line was obtained from the Pasteur Institute of Iran.

    Techniques: Quantitative RT-PCR, Gene Expression, Amplification, Quantitative Proteomics